Patient & Survivor Care
Commentary
‘The Oncologist Without the Pathologist Is Blind’: GI Cancer Updates at ASCO 2024
Is perioperative FLOT truly superior to the CROSS protocol in esophageal cancer?
Feature
New ADC results mixed in metastatic breast cancer
While T-DXd showed promise for yet another indication at ASCO, other findings underscored that much still remains to be learned about this drug...
From the Journals
Sorafenib Plus TACE Prolongs Survival in Recurrent HCC
Patients with recurrent intermediate-stage HCC and positive microvascular invasion receive either sorafenib plus TACE or TACE alone in a...
From the Journals
Weight Loss Drugs Cut Cancer Risk in Diabetes Patients
Researchers examine electronic health records of patients who had type 2 diabetes, no prior diagnosis of obesity-related cancers, and had been...
Conference Coverage
Adjuvant Avelumab Benefits Seen in High Risk, Triple Negative BC
Researchers conduct first randomized phase 3 trial of patients with TNBC treated with adjuvant avelumab.
Conference Coverage
Clinical Controversy: Standard Dose or Baby TAM for Breast Cancer Prevention?
Docs debate which dose of tamoxifen is best for reducing breast cancer risk at the ESMO Breast Cancer Congress.
Feature
Trifluridine/tipiracil Plus Bevacizumab: A Game Changer in Late-Stage Refractory mCRC
The regimen can provide significant psychological benefits to patients, says expert.
From the Journals
Urticaria Linked to Higher Cancer Risk, Study Finds
Researchers compare the incident cancer risk between patients with urticaria and the general population using data from Danish healthcare...
Feature
Cancer Drug Shortages Continue in the US, Survey Finds
Not having enough of a significant spectrum of generic chemotherapies and supportive care medications is an ongoing issue, NCCN surveys suggest....
Conference Coverage
New Tools for Monitoring Multiple Myeloma
“The detection of this minimal residual disease corresponds with a significant reduction in survival,” according to an expert from the University...
Conference Coverage
EMA Greenlights Four Drugs for Bladder and Other Cancers
Among the drug approvals the CHMP endorsed was Balversa for the treatment of urothelial carcinoma.